Ignite Creation Date:
2024-05-06 @ 8:15 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06304974
Status:
RECRUITING
Last Update Posted:
2024-03-28
First Post:
2024-03-05
Brief Title:
A Study Comparing BL-B01D1 With Chemotherapy of Physicians Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Sponsor:
Sichuan Baili Pharmaceutical Co Ltd
Organization:
Sichuan Baili Pharmaceutical Co Ltd
Study Overview
Official Title:
A Phase Ill Randomized Controlled Clinical Study Comparing BL-B01D1 With Chemotherapy of Physicians Choice as Second Line Treatment in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma After Failure of PD-1PD-L1 Monoclonal Antibody in Combination With Platinum-based Chemotherapy
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a registered phase Ill randomized open-label multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with recurrent or metastatic esophageal squamous cell carcinoma after failure of PD-1PD-L1 monoclonal antibody in combination with platinum-based chemotherapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None